MONTREAL, May 6, 2024 – MY01, an innovative medical technology company dedicated to revolutionizing the diagnosis of acute compartment syndrome, is pleased to introduce the appointment of Andrew Morris as its Chief Commercial Officer.

An established Medical Device leader with nearly two decades of experience building high-performing sales and marketing teams, Mr. Morris brings extensive knowledge and expertise to the MY01 team. His demonstrated passion for building strong customer relationships and, more importantly, his deep-rooted desire to improve patient outcomes, are qualities that align perfectly with MY01’s mission. Andrew’s ability to align a strategic vision with commercial execution will be paramount to our ability to increase our impact. 

As Chief Commercial Officer, Andrew will not only lead all commercial activities at MY01, including sales, marketing, and business development but also bring his strategic insights and leadership to the forefront. His ability to drive growth, expand our market presence, and explore new opportunities will create value for our stakeholders and potential partners.

“We are thrilled to welcome Andrew to the MY01 team,” said Charles Allan, CEO of MY01. “His extensive experience and deep understanding of the industry make him the ideal candidate to lead our commercial efforts. We are confident his leadership will help us achieve our goals and drive continued success for MY01.”

Andrew commented, “I am deeply honored to be a part of MY01 and contribute towards impacting our ability to develop a new standard of care in diagnosing acute compartment syndrome. It’s energizing to work with such a talented team that has designed a remarkable solution to a complex and serious problem that has the potential to make a real difference in people’s lives.”

About MY01, Inc :

MY01, Inc. is a privately held commercial-stage medical technology company on a mission to empower healthcare professionals with objective data to aid in the diagnosis of compartment syndrome, thereby improving patient outcomes. MY01 believes that incorporating actionable, quantitative data at the bedside can augment clinical assessments and provide more effective care. Since its establishment in 2015, MY01, Inc., headquartered in Montreal, Quebec, has leveraged its expertise in microsensing technology to provide innovative diagnostic solutions.